Insider Trades
Common-stock transactions that officers, directors and 10% owners of healthcare companies report to the SEC on Form 4, from 2006 to today, newest first.
Insider filings are public records and are not a recommendation.
Results
25+ transactions, newest first
| Date | Insider | Relationship | Company | Transaction | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Adler Reid G. | Chief Legal Officer | Vistagen Therapeutics, Inc.VTGN | OtherA · Grant or award from the company | 36,818 | $0.19 | $6,995.42 | 60,868Direct | Form 4 filed 2 Jul 2026, on sec.gov (opens in a new tab)Filed 2 Jul 2026 | |
| Tressler Nick B. | Chief Financial Officer | Vistagen Therapeutics, Inc.VTGN | OtherA · Grant or award from the company | 11,712 | $0.19 | $2,225.28 | 11,712Direct | Form 4 filed 2 Jul 2026, on sec.gov (opens in a new tab)Filed 2 Jul 2026 | |
| Singh Shawn | Director, President and CEO | Vistagen Therapeutics, Inc.VTGN | OtherA · Grant or award from the company | 36,818 | $0.19 | $6,995.42 | 54,846Direct | Form 4 filed 2 Jul 2026, on sec.gov (opens in a new tab)Filed 2 Jul 2026 | |
| Prince Joshua S. | Chief Operating Officer | Vistagen Therapeutics, Inc.VTGN | OtherA · Grant or award from the company | 4,386 | $0.56 | $2,456.16 | 15,249Direct | Form 4 filed 5 Jan 2026, on sec.gov (opens in a new tab)Filed 5 Jan 2026 | |
| Singh Shawn | Director, President and CEO | Vistagen Therapeutics, Inc.VTGN | OtherA · Grant or award from the company | 7,541 | $1.70 | $12,819.70 | 18,028Direct | Form 4 filed 1 Jul 2025, on sec.gov (opens in a new tab)Filed 1 Jul 2025 | |
| Adler Reid G. | Chief Legal Officer | Vistagen Therapeutics, Inc.VTGN | OtherA · Grant or award from the company | 7,541 | $1.70 | $12,819.70 | 24,050Direct | Form 4 filed 1 Jul 2025, on sec.gov (opens in a new tab)Filed 1 Jul 2025 | |
| Prince Joshua S. | Chief Operating Officer | Vistagen Therapeutics, Inc.VTGN | OtherA · Grant or award from the company | 4,882 | $1.70 | $8,299.40 | 10,863Direct | Form 4 filed 1 Jul 2025, on sec.gov (opens in a new tab)Filed 1 Jul 2025 | |
| Anderson Cynthia Lynn | CHIEF FINANCIAL OFFICER | Vistagen Therapeutics, Inc.VTGN | OtherA · Grant or award from the company | 6,617 | $1.70 | $11,248.90 | 12,801Direct | Form 4 filed 1 Jul 2025, on sec.gov (opens in a new tab)Filed 1 Jul 2025 | |
| Anderson Cynthia Lynn | CHIEF FINANCIAL OFFICER | Vistagen Therapeutics, Inc.VTGN | OtherA · Grant or award from the company | 2,592 | $2.51 | $6,505.92 | 6,184Direct | Form 4 filed 13 Jan 2025, on sec.gov (opens in a new tab)Filed 13 Jan 2025 | |
| Prince Joshua S. | Chief Operating Officer | Vistagen Therapeutics, Inc.VTGN | OtherA · Grant or award from the company | 3,310 | $2.51 | $8,308.10 | 5,981Direct | Form 4 filed 13 Jan 2025, on sec.gov (opens in a new tab)Filed 13 Jan 2025 | |
| Adler Reid G. | CHF CORP DEVEL OFF, GEN COUNS | Vistagen Therapeutics, Inc.VTGN | OtherA · Grant or award from the company | 4,854 | $2.96 | $14,367.84 | 16,509Direct | Form 4 filed 2 Jul 2024, on sec.gov (opens in a new tab)Filed 2 Jul 2024 | |
| Prince Joshua S. | Chief Operating Officer | Vistagen Therapeutics, Inc.VTGN | OtherA · Grant or award from the company | 2,671 | $2.96 | $7,906.16 | 2,671Direct | Form 4 filed 2 Jul 2024, on sec.gov (opens in a new tab)Filed 2 Jul 2024 | |
| Singh Shawn | Director, CHIEF EXECUTIVE OFFICER | Vistagen Therapeutics, Inc.VTGN | OtherA · Grant or award from the company | 4,854 | $2.96 | $14,367.84 | 10,487Direct | Form 4 filed 2 Jul 2024, on sec.gov (opens in a new tab)Filed 2 Jul 2024 | |
| Anderson Cynthia Lynn | CHIEF FINANCIAL OFFICER | Vistagen Therapeutics, Inc.VTGN | OtherA · Grant or award from the company | 3,592 | $2.96 | $10,632.32 | 3,592Direct | Form 4 filed 2 Jul 2024, on sec.gov (opens in a new tab)Filed 2 Jul 2024 | |
| Singh Shawn | Director, CHIEF EXECUTIVE OFFICER | Vistagen Therapeutics, Inc.VTGN | OtherA · Grant or award from the company | 167 | $1.72 | $287.24 | 5,633Direct | Form 4 filed 3 Jan 2024, on sec.gov (opens in a new tab)Filed 3 Jan 2024 | |
| Adler Reid G. | CHF CORP DEVEL OFF, GEN COUNS | Vistagen Therapeutics, Inc.VTGN | OtherA · Grant or award from the company | 167 | $1.72 | $287.24 | 11,655Direct | Form 4 filed 3 Jan 2024, on sec.gov (opens in a new tab)Filed 3 Jan 2024 | |
| COMMODORE CAPITAL LP | 10% owner | Vistagen Therapeutics, Inc.VTGN | BuyP · Open-market or private purchase | 775,756 | $23.15 | $17,958,751.40 | 1,575,000Indirect, By Commodore Capital Master LP | Form 4 filed 9 Aug 2023, on sec.gov (opens in a new tab)Filed 9 Aug 2023 | |
| DOTSON JERROLD DUANE | VP, CFO | Vistagen Therapeutics, Inc.VTGN | OtherA · Grant or award from the company | 167 | $1.59 | $265.53 | 3,671Direct | Form 4 filed 5 Jul 2023, on sec.gov (opens in a new tab)Filed 5 Jul 2023 | |
| Singh Shawn | Director, CHIEF EXECUTIVE OFFICER | Vistagen Therapeutics, Inc.VTGN | OtherA · Grant or award from the company | 167 | $1.59 | $265.53 | 5,466Direct | Form 4 filed 5 Jul 2023, on sec.gov (opens in a new tab)Filed 5 Jul 2023 | |
| Adler Reid G. | CHIEF LEGAL OFFICER | Vistagen Therapeutics, Inc.VTGN | OtherA · Grant or award from the company | 167 | $1.59 | $265.53 | 11,488Direct | Form 4 filed 5 Jul 2023, on sec.gov (opens in a new tab)Filed 5 Jul 2023 | |
| DOTSON JERROLD DUANE | VP, CFO AND SECRETARY | Vistagen Therapeutics, Inc.VTGN | OtherA · Grant or award from the company | 5,000 | $0.09 | $450 | 105,111Direct | Form 4 filed 3 Jan 2023, on sec.gov (opens in a new tab)Filed 3 Jan 2023 | |
| Singh Shawn | Director, CHIEF EXECUTIVE OFFICER | Vistagen Therapeutics, Inc.VTGN | OtherA · Grant or award from the company | 5,000 | $0.09 | $450 | 158,998Direct | Form 4 filed 3 Jan 2023, on sec.gov (opens in a new tab)Filed 3 Jan 2023 | |
| GIN JERRY B | Director | Vistagen Therapeutics, Inc.VTGN | BuyP · Open-market or private purchase | 100,000 | $0.18 | $18,000 | 100,000Indirect, By Spouse | Form 4 filed 22 Aug 2022, on sec.gov (opens in a new tab)Filed 22 Aug 2022 | |
| GIN JERRY B | Director | Vistagen Therapeutics, Inc.VTGN | BuyP · Open-market or private purchase | 100,000 | $0.18 | $18,000 | 100,000Direct | Form 4 filed 22 Aug 2022, on sec.gov (opens in a new tab)Filed 22 Aug 2022 | |
| Singh Shawn | Director, CHIEF EXECUTIVE OFFICER | Vistagen Therapeutics, Inc.VTGN | BuyP · Open-market or private purchase | 600,000 | $0.17 | $102,000 | 626,234Indirect, By The 1997 Singh Family Trust U/R/D 05/29/97 | Form 4 filed 18 Aug 2022, on sec.gov (opens in a new tab)Filed 18 Aug 2022 |
Source: SEC EDGAR Form 4 filings and the SEC Insider Transactions Data Sets (2006 onward). Each row links to its Form 4 filing. Values are shares times the reported price. Nothing here is investment advice.